Introduction
Aerobic organisms possess antioxidant defense systems that modulate reactive oxygen species (ROS). The superoxide dismutases (SODs) catalyze the dismutation of superoxide radicals into hydrogen peroxide and molecular oxygen. Hydrogen peroxide is further detoxi®ed by catalase and glutathione peroxidase (Halliwell and Gutteridge, 1989) . Three distinct SODs are found in human cells: a homodimeric cytosolic CuZnSOD (McCord and Fridovich, 1969) ; an extracellular homotetrameric glycosylated CuZnSOD (EC-SOD) (Marklund, 1982) ; and a mitochondrial matrix homotetrameric MnSOD (Weisiger and Fridovich, 1973) .
Accumulating data suggest that MnSOD constitutes one of the major cellular defense mechanism against the toxic eects of agents that cause oxidative stress. It has been demonstrated that MnSOD knockout mice develop cardiomyopathy and neonatal lethality, whereas independent disruption of the genes for CuZnSOD and ECSOD isoenzymes result in viable, normal mice under nonstress conditions (reviewed in Yen and St.Clair, 1997) . Furthermore, transgenic mice expressing human MnSOD in the mitochondria are protected from oxygen-induced lung injury (Wispe et al., 1992) , acute adriamycin induced cardiac injury (Yen et al., 1996) , and ischemia-induced brain injury (Keller et al., 1998) .
Numerous studies using gene transfection have demonstrated that transfection of MnSOD into tumor cells reverse the malignant phenotypes of tumor cells, suggesting that MnSOD functions to suppress tumorigenicity (reviewed in St.Clair, 1997) . Transfection of human MnSOD cDNA into mouse ®broblasts prevents radiation-induced neoplastic transformation (St.Clair et al., 1992) . Expression of the human MnSOD gene in mouse C3H10T1/2 cells enhances cellular differentiation upon treatment with 5-azacytidine . The malignant phenotype of human melanoma cells was suppressed by introduction of human chromosome 6 where the MnSOD gene is located (Trent et al., 1990) or transfection of a human MnSOD cDNA (Church et al., 1993) . Overexpression of MnSOD suppressed the malignant phenotypes of human breast cancer cells (Li et al., 1995) , human glioma cells (Zhong et al., 1997) , and mouse epidermal cells (Amstad et al., 1997) . The number of cells required to produce tumors in syngenic mice was markedly increased for the MnSOD-transfected murine ®brosarcoma cell lines (MnSOD-Fsa-II) compared to the vector-transfected control cells . The frequency of metastases was reduced in syngenic mice carrying the MnSOD transfected-FsaII cells compared to the mice bearing the control FsaII cells (Saord et al., 1994) . Furthermore, the radiation dose required to control one-half of the irradiated tumor (TCD50) was greatly reduced when the MnSOD-FsaII cells were transplanted and irradiated in vivo under hypoxic conditions (Urano et al., 1995) . Taken together, the evidence from these studies supports a hypothesis proposed by Oberley and Oberley (1984) that MnSOD plays an important role in the prevention of cancer development.
It has been shown that many types of human cancer cells have reduced MnSOD activity compared to their appropriate normal counterpart cells (Oberley and Buettner, 1979) . The reduced level of MnSOD activity in human cancer cells is not due to a defect in the primary structure of the MnSOD protein, a change in the dosage of the MnSOD gene, or a decrease in the stability of MnSOD mRNA in tumor cells, but rather is due to defects in the expression of the gene (St.Clair and Holland, 1991) . We have previously cloned and sequenced the entire human MnSOD gene, including a 0.78 kb 5'¯anking region, from a genomic library obtained from normal human lung ®broblast cells. The gene is characterized by the lack of TATA or CAAT box and the presence of a GC-rich region containing multiple SP-1 binding sites (Wan et al., 1994) . To elucidate the cause for the reduced expression of human MnSOD in tumor cells, in the present study, we have further sequenced into the 5'¯anking region of the human MnSOD gene and compared that to the 5'¯anking regions of the human MnSOD gene from several tumor cell lines. The results demonstrate three heterozygous mutations in the promoter region of the human MnSOD gene in ®ve of 14 tumor cell lines examined. The eect of these mutations on the transcription activity of the human MnSOD promoter was also determined.
Results

Cloning and characterization of 5'¯anking region of the human MnSOD gene
We previously isolated and characterized the human MnSOD gene from a human lung ®broblast cell line, WI-38 (Wan et al., 1994) . To further elucidate the mechanism(s) for the reduced expression of human MnSOD in tumor cells, we searched for defects in the 5'¯anking region which might alter MnSOD gene transcription. A BamHI (B7) fragment spans a 5' anking region containing 73400 bp upstream to +257 bp downstream from the transcription initiation site was subcloned into M13mp18 and M13mp19 from a l clone. The nucleotide sequence of B7 was determined on both strands using multiple overlapping M13 subclones (Figure 1 ). Sequence analysis revealed putative transcription factor binding sites for NF-kB, AP-1, ARE, AP-2 and SP-1 in the 5'¯anking region, suggesting that the expression of the human MnSOD gene may be controlled by these regulatory elements ( Figure 2 ). The putative promoter region contains GC boxes with consensus binding sites for SP-1 and AP-2 transcription factors. SP-1 binding sites either overlap themselves (SP-1/SP-1) or AP-2 binding sites (AP-2/SP-1).
Characteristics of the 5'¯anking region of the MnSOD gene in cancer cells
Four primer sets were used to amplify overlapping fragments from the 5'¯anking region and a 70 bp downstream from the transcription initiation site of the human MnSOD gene (Figure 3 ) from the genomic DNA isolated from SV40 transformed human lung ®broblasts (VA13), human colon adenocarcinoma (HT29) cells and human promyelocytic leukemia (HL60) cells. The sizes of PCR products ampli®ed from the genomic DNA of human tumor cell lines and the normal cell line were identical and corresponded to the expected sizes. These results indicated that there are no major additions or deletions in the 5'¯anking region of the human MnSOD gene in the tumor cell lines examined. Detailed DNA sequence analysis in both directions of the PCR products showed no mutations in the PCR-1, PCR-2 and PCR-3 products. However, three mutations were identi®ed in the PCR-4 region in the HT29 tumor cell line, but not in VA13 and HL60 cell lines (Figure 4 ). These mutations were, a C to T change at 7102 , a C to G change at 738 and insertion of an A in the eleven straight G region at 793. The signi®cance of mutations in this region was suspected because the PCR-4 region includes multiple binding sites for SP-1 proteins which are required for the basal transcription of the human MnSOD gene (Yeh et al., to be published elsewhere). When the PCR-4 products were examined in additional colon and noncolon cancer cell lines (Table 1) , the same three mutations were detected in three of ®ve colon cancer cell lines tested (Table 2) . A human glioblastoma cell line, U87, and a human ®brosarcoma cell line, HT-1080 also carried the three mutations. However, these mutations were not detected in the four human breast cancer lines and the other tumor cell lines examined. To determine whether the mutations are heterozygous in nature, the corresponding PCR-4 fragments from the tumor cell lines were also directly sequenced by a cycle-sequencing method. The results from direct sequencing of the PCR products reveal evidence of heterozygosity at all three mutation sites ( Figure 5 ).
Computer analysis predicted that the mutations would alter recognition sites for several restriction endonucleases ( Table 2 ). The A insertion at 793 and the C to G transversion at 738 would create a new MnlI (CCTCN 7 ) and an AhaI (CCSGG) restriction digestion sites respectively. However, the C to T transition at 7102 would result in loss a of the ApaI (GGGCCC) restriction digestion site. To verify these predictions, analysis of restriction fragment length polymorphisms (RFLP) was performed to compare restriction digestion patterns in the tumor and normal cells. Cloned fragments (covering the promoter fragment from 7210 to +24) were digested with ApaI and then subjected to an agarose gel electrophoresis. The normal fragment was digested by ApaI to yield two bands (138 bp and 108 bp). The mutated fragment from tumor cells yields only one band (246 bp) due the loss of the Apa I site ( Figure 6 ).
Reduction of transcription activity from the mutated promoter
To determine whether mutations in the human MnSOD promoter will aect the transcription of MnSOD gene, PCR-ampli®ed promoter fragments (7154 to 24), with or without the three mutations, were obtained from a normal and a cancer cell lines and subcloned into both pGL3-basic and pGL3-enhancer vector. VA13 cells were transiently transfected with the resulting plasmid constructs and the promoter activities were evaluated by a ®re¯y luciferase reporter gene expression normalized to a co-transfected renilla luciferase as a control for transfection eciency. The normalized luciferase reporter activities indicate that the mutations in the promoter signi®cantly reduced promoter activity ( Figure 7 ). Compared to Figure 2 DNA sequence of the 5'¯anking region of the human MnSOD gene. The transcription initiation site is numbered as +1. Sequences are numbered relative to the transcription initiation site (+1). Potential transcription regulatory binding sites for NF-kB, ARE, AP-1, SP-1 and AP-2 are boxed. The arrow heads indicate the strand by which consensus sequences are detected the normal promoter activities, the mutated promoter activities decreased by more than 50% in the pGL3 constructs and 90% in the pGL3-enhancer constructs, respectively. Multiple independent transfections were performed with similar results.
Changes of the transcription factor binding pattern in the mutated promoter
A computerized search by a transcription factors database (MacVector, Kodak) identi®ed multiple consensus binding sites for SP-1 and AP-2 transcription factors in the promoter of the human MnSOD gene ( Figures 2, and 3 ). Our analysis predicted that AP-2 but not SP-1 binding pattern would be changed in the mutant promoter. The C to G transversion at 738 creates an additional AP-2 binding site and the C to T transition at 7102 eliminates an AP-2 binding site, respectively. To con®rm the predicted alteration of the transcription factor binding sites in the mutated promoter, in vitro DNase I footprinting analysis was performed using puri®ed SP-1 and AP-2 proteins with a radio-labeled promoter fragment (7210 to +24). Footprints were observed at multiple binding sites for SP-1 and AP-2 within this fragment (Figure 8 ). One predicted SP-1 site close to the transcription initiation site was apparently weak and could not be detected. In the normal promoter fragment, ®ve strong protected regions were observed with AP-2 protein that corresponded to sites 1, 2, 3, 5 and 6. Some AP-2 binding sites also overlap SP-1 binding sites (SP-1/AP-2). When AP-2 protein was used with the mutant promoter fragment, an additional AP-2 protected site was observed (region 4 in Figure 8 ) which is consistent with the result from computerized search. However, footprinting did not show elimination of an AP-2 binding site by the C to T transition at 7102. No change was found in the SP-1 binding pattern.
Discussion
MnSOD has been proposed to be a new type of tumor suppressor gene because the activity of MnSOD is reduced in many tumor and transformed cells and overexpression of MnSOD suppresses tumorgenicity in many tumor types. Previous observations from our laboratory suggested that the reduced level of MnSOD activity in human cancer cells was likely due to defects in transcription of the gene, because the level of the steady state MnSOD mRNA was reduced in cancer cells without a change in the mRNA stability (St.Clair and Holland, 1991) . In the present study, we found that ®ve of 14 tumor cell lines examined carry three common mutations in the promoter region of the MnSOD gene. Although one common problem in studies using cell lines is the possibility for occurrence in culture of sporadic mutations that are irrelevant to the genesis of tumor phenotypes, this is unlikely to be the case for the three mutations found in the human MnSOD gene for the following reasons: (1) These mutations occur as a set of three mutations at the same positions in all ®ve cell lines; (2) These mutations appear in three of ®ve human colon cancer cell lines, but not in any of the four human breast cancer cell lines examined. Taken together, these results suggest that mutations in the promoter region of the human MnSOD gene may be predominant in colon cancer.
The transcriptional activity driven by the mutated promoter from the cancer cells was signi®cantly reduced under both enhanced and non-enhanced conditions. This result suggests that the reduced MnSOD activity in some cancer cells is, at least in part, due to a defect in the promoter of the gene. As shown in Table 2 , the mutations have not been detected in all cancer cell lines examined. In fact, no mutation was found in the VA13 cells. It has previously been established that the MnSOD activity in cultured cells change greatly with growth stage and growth conditions . However, under all conditions examined, the MnSOD activity in the VA13 cells was always lower than that in their normal counterparts. We have also shown previously that the MnSOD mRNA level was also lower in the VA13 cells compared to their normal counterparts (St.Clair and Holland, 1991) . These ®ndings suggest that other contributing factors also play a role in reducing the expression of the human MnSOD gene in tumor cells. (Michell et al., 1987) . Thus, although it remains to be investigated, it is possible that modulation of AP-2 activity by SV40-T antigen may play a role in the expression of the MnSOD gene in the VA13 cells.
We previously reported that the human MnSOD gene is a single-copy gene consisting of ®ve exons interrupted by four introns with typical splice junctions (Wan et al., 1994) . The GC-rich characteristic of the MnSOD promoter is conserved among mouse (Jones et al., 1995) , bovine (Meyrick and Magnuson, 1994) , rat (Ho et al., 1991) , and human (Wan et al., 1994) . Mammalian gene promoter with GC-rich characteristics, have multiple binding sites for SP-1 and AP-2 in the 5' upstream region that are essential for the promoter activity (Getman et al 1995; Li et al., 1997; Tang et al., 1997) . In the present study, we showed that a fragment from 7210 to +24 contains a promoter region suitable for initiating gene transcription. The mutations in this promoter found in the ®ve tumor cell lines are located in the GC boxes suggesting that the expression of MnSOD activity in these cancer cells might also be modulated by interaction between SP-1 and AP-2.
SP-1 is a ubiquitous transcription factor present in all mammalian cells. SP-1-responsive promoters usually contain multiple GC boxes proximal to the transcription initiation site (Briggs et al., 1986) . SP-1 binds to GC box promoter element and selectively activates mRNA synthesis by RNA polymerase II Tjian, 1983, 1985) . A number of closely regulated genes have been reported to possess promoters with a high frequency of G and C residues suggesting that SP-1 plays a key role in transcription of these genes (Baker et al., 1996; Moat et al., 1996; Cohen et al., 1997; Dharmavarm et al., 1997) . However, SP-1 binding anity and transcription properties can be altered by interaction with other co-factors. SP-1 recognition sequences are often found near binding sites for other transcription factors, such as CTF/NF-1 (Jones et al., 1985) , AP-1 (Lee et al., 1987) , NF-kB (Perkins et al., 1993) , C/EBP (LoÂ pezRodrõÂ guez et al., 1997) and AP-2 (Getman et al., 1995; Tang et al., 1997) , which suggests that these factors may act in conjunction with each other to modulate transcription. Interestingly, AP-2 binding sites have been detected in almost all SP-1-responsive promoters and found to be involved in control of gene expression. Several studies reported that AP-2 acts positively to increase the transcription in tissue-speci®c manner (Williams et al., 1988; Mitchell et al., 1991) . However, Getman et al., (1995) reported that AP-2 can function as a repressor of human and mouse ACHE transcription because AP-2 can compete with SP-1 for overlapping binding sites located within a limited portion of a promoter region. Our data showed that mutations in the human MnSOD promoter in cancer cells lead to a change in the binding pattern for AP-2, but not for SP-1.
Human SP-1 activates transcription from many eukaryotic promoters. SP-1 activation depends on three Zn-®nger structures responsible for DNA binding and at least one of two glutamine-rich regions that are required for transcription activation (Kadonaga et al., 1988; Courey and Tjian, 1988) . Contact between SP-1 proteins at nonadjacent sites on a short DNA fragment causes the formation of extrastructures, such as DNA-looping (Su et al., 1991) or DNA-bending (Ikeda et al., 1993) . The human MnSOD promoter is composed of multiple SP-1 and AP-2 binding sites on a 200 bp DNA fragment. The binding of multiple SP-1 and AP-2 proteins to their recognition sites might generate a speci®c structure that are required for the cooperative activation of other regulatory proteins and the recruitment of RNA polymease II to activate synergistic transcription of this gene. It is tempting to speculate that the mutations in the MnSOD promoter may change the binding pattern of activators and might interfere with DNAprotein interactions leading to a destruction of this speci®c structure, or might change the speci®c structure leading to inhibition of protein-protein interactions in the initiation complex.
It has been demonstrated that cellular and viral gene have the potential to form secondary structures, particularly in the promoters with GC-rich characteristics. For example, promoter of immediate early (IE) genes in the human cytomegalovirus (CMV) has been predicted to form a cruciform structure through the surrounding sequences with 18 nucleotides being unpaired. This secondary structure in the promoter is related to a high level of transcription of the IE gene (Thomsen et al., 1984) . We propose that a putative DNA-looping structure could be formed through the surrounding sequences in the human MnSOD promoter as illustrated in Figure 9 . In this case, the eleven unpaired guanonsine loop might provide a speci®c binding domain for activation of transcription. This Putative cruciform structure with 11-guanine unpaired loop located in the human MnSOD promoter. Three SP-1 and one AP-2 binding sites located in the DNA-looping structure are marked. Sites where mutations may disrupt the proposed structure are indicated loop structure contains three SP-1 and AP-2 binding sites that are required for basal transcription of the gene. Deletion of this entire region has resulted in a greater than 90% decrease of transcription activity (data not shown). Two of the three mutations located in this region might interfere with the formation of the secondary structure, especially, the C to T transition at 7102 may result in an alteration of the putative loop structure.
In summary, the present study is the ®rst to demonstrate that the reduced level of MnSOD activity in tumor cells is partly due to a defect in the promoter region of the gene. Mutations in the promoter region resulted in a change in DNA binding pattern of the AP-2 transcription factor. Modulation of transcription factors binding pattern might lead to a change of sequence-speci®c interaction between DNA-protein or protein-protein in the transcription initiation complex. The ®nding that these mutations do not occur in all tumor cell lines examined suggests that other potential mechanisms that play a causal role in the reduction of MnSOD activity in some cancer cells exist and are currently being investigated.
Materials and methods
Cell culture
All cell lines listed in Table 1 were obtained from the American Type Culture Collection (ATCC), grown in RPMI 1064 (leukemia cells), BME (VA13 cells) or DMEM (all other cells) supplemented with 10% bovine serum and insulin (T74D only), and maintained at 378C in a humidi®ed atmosphere of 95% air and 5% CO 2 . Cultured con¯uent cells were washed three times with phosphate buer saline (PBS), harvested with a cell scraper, and centrifuged at 2000 r.p.m for 5 min. The cell pellets were stored at 7208C prior to isolation of genomic DNA.
An SV-40 transfected human lung ®broblast cell line (WI-38 subline VA13) was used for analysis of promoter function by transient transfection with MnSOD promoter driven luciferase reporter gene. The cells were plated at a density of 16 10 5 cells in a 32 mm tissue culture dish containing 4 ml of Eagle's basal medium (BME) supplemented with 10% fetal bovine serum and incubated at 378C for 16 h before transfection of the DNA. The cells were harvested 60 h after transfection.
Isolation of genomic DNA from cultured cells
Genomic DNA was isolated from cultured cancer cells using a DNA Micro-Extraction Kit according to the manufacture's instruction (Stratagene). In brief, approximately 10 8 cells in 300 ml of PBS were lysed by adding pronase to a ®nal concentration of 400mg/ml and followed by a 30 min incubation at 608C. Cellular protein was removed by salt precipitation and centrifugation at 20006g for 15 min at 48C. RNA was removed by incubation of the solution for 30 min at 378C with RNase at a ®nal concentration of 25 mg/ml. The DNA was recovered by ethanol precipitation, estimated spectrophotometrically and stored at 7208C. A high ®delity pfu DNA polymerase (Stratagene) was used to minimize the error rate in the DNA synthesis by PCR (Flaman et al., 1994) .
PCR was carried out in 50 ml reaction mixture containing 20 mM Tris-HCl, pH 8.8, 2 mM MgSO 4 , 10 mM KCl, 10 mM (NH4) 2 SO 4 , 0.1% Triton X-100, 1 mg/ml nuclease-free BSA, 10 mM each of dATP, dCTP, dGTP and dTTP, 0.2 pM of each primer, 6% DMSO, 1 mg genomic DNA, and 2.5 U p.f.u DNA polymerase. The thermal cycling settings for PCR-1, PCR-2 and PCR-3 include a 5 min initial denaturation at 958C followed by 35 ampli®cation cycles (1 min denaturation at 948C, 1 min annealing at 55 ± 658C depending on the primer sets, and 1.5 to 3 min extension at 728C depending on the length of PCR products, ®nished with a ®nal extension at 728C for 10 min). 7-deaza-2'-dGTP (C7 dGTP, Boehringer Mannheim) was used to amplify the PCR-4 because of its GC rich nature (Innis et al., 1988) . For ampli®cation of PCR-4, the conditions were changed to, 3 : 1 C7 dGTP : dGTP instead of dGTP in the dNTP mixture and 80 mM dNTP. Thermal cycling settings include initial denaturation at 98 8C for 10 min, ®ve cycles of 95 8C for 45 s, and 72 8C for 1 min for primer annealing, followed by 35 cycles consisting of denaturation at 958C for 45 s, annealing at 60 8C for 1 min, extension at 72 8C for 1.5 min (auto segment extension of 2 s per cycle) and ®nal extension at 728C for 10 min. The PCR products were analysed by on a 1% agarose gel in Tris-acetate buer with ethidium bromide staining. The products of PCR-1, PCR-2 and PCR-3 were puri®ed from the agarose gels using a GeneClean Kit (Bio101) and the product of PCR-4 by a MC membrane (Millipore) according to the manufactures' recommendations.
Cloning
To determine the nucleotide sequence of the 5'¯anking region of the human MnSOD gene, a BamHI fragment (B7) containing a 3.4 kb 5'¯anking region was subcloned into M13mp 18 from the 39b l clone (Figure 1 ). This l clone was derived from a genomic library prepared from human lung ®broblast cells and has been described previously (Wan et al., 1994) . This l clone includes a complete coding region of the human MnSOD gene in addition to a 5'¯anking region and a 3'¯anking region (Wan et al., 1994) . The B7 region was mapped by restriction endonuclease digestion. Small fragments obtained from the digested B7 were subcloned into multicloning sites of M13mp18 and/or M13mp 19 vectors for DNA sequencing.
To clone PCR products ampli®ed from the 5'¯anking region of human MnSOD gene, a PCR-Script Amp SK(+) vector (Stratagene) was used. The vector was derived from the pBluescript + II SK (+) phagemid by addition of an SrfI site, which is a rare-cleavage restriction enzyme within the multiple cloning sites. SrfI recognizes 8 bp oligonucleotide sequence 5'-GCCC|GGGC-3' and its cutting site is the same as SmaI (5'-CCC|GGG-3') . The use of SrfI in the ligation maintains the concentration of SmaI digested vector DNA by preventing self-ligation of the vector and allows rapid and ecient blunt-ended cloning of the PCR products ampli®ed by p.f.u. DNA polymerase. Screening of the PCR products were performed by the blue-white phenotype from acomplementation of lac Z gene and restriction pattern of the recombinant plasmids. For DNA sequencing, the plasmid DNA was prepared from 1.5 ml of LB culture and puri®ed by polyethylene glycol 8000 precipitation.
Sequence analysis
To determine the DNA sequence in the 5'¯anking region of the human MnSOD gene, single-strand DNA templates were prepared from M13 clones and the nucleotide sequence was determined on both strands by Sanger's dideoxynucleotide chain-termination method (Sanger et al., 1977) with Sequenase 2.0 (Amersham). A dITP reaction mix was used to sequence the GC rich region. Multiple overlapping fragments were sequenced at least twice in each direction and the DNA sequence was analysed by MacVector software (Kodak).
To investigate mutations in the 5'¯anking region, thirty four oligonucleotides complementary to de®ned DNA sequences of the 5'¯anking region were synthesized as DNA sequencing primers in both forward and reverse directions. DNA sequence analysis was performed by manual method (Thermo sequenase cycle sequencing kit, Amersham) and automatic sequence method (Applied Biosystem) according to the manufactures instructions. Direct sequencing of PCR products was performed to con®rm that the detected mutations are heterozygous in nature. 7-deaza-dGTP and 10% DMSO were used for sequencing the GC rich region.
RFLP analysis
Analysis of restriction fragment length polymorphisms was used to con®rm the changes of restriction enzyme digestion sites caused by the mutations. The cloned mutated and non-mutated PCR products were cut with appropriate restriction enzymes, subjected to electrophoresis through a 2% of agarose gel in Tris-borate buer, stained with ethidium bromide, and photographed.
Analysis of the promoter activities
A luciferase reporter system (Promega) was used to determine changes of the promoter activity due to mutations in the human MnSOD promoter. Plasmid constructs were prepared using pGL3-Basic and pGL3-SV40 enhancer vectors to subclone each promoter region upstream of the ®re¯y luciferase reporter gene. A set of PCR primers with recognition sequences for KpnI and BglII digestion on the terminals was used to amplify the promoter region 7154 to +24 from the cloned PCR-4 products. The sequences of oligonucleotide primers were: 5'-CGGGGTACCACAGGCACGCAGGGCACCCCCGG-GGT-3' and 5'-GGAAGATCTGCCGAAGCCACCACA-GCCACGAGT-3'. The PCR condition was the same as that described for the PCR-4. The PCR products were cloned into the luciferase reporter vectors within KpnI and BglII sites.
The resulting plasmids were transiently transfected into the VA13 cells by the calcium phosphate mediated transfection method (Wigler et al., 1977) . To control for dierences in transfection eciencies, an additional vector (Renilla luciferase, co-vector) was co-transfected as an internal control. A mixture of 3.6 mg vector DNA and 0.4 mg covector DNA (10 : 1) were transfected into the cells in a 32 mm tissue culture dish. Sixty hours after transfection, the cells were washed with PBS three times, harvested, and lysed by incubation with 200 ml passive lysis buer (Promega) at room temperature for 30 min. Fire¯y and renilla luciferase activities were measured by a Dual-luciferases assay system using a TD-20/20 Luminometer (Promega). The mutant promoter activities were compared to the wild type promoter based on the normalized luciferase expression. Data were evaluated using a statistical analysis system (SAS Institute Inc., Cary, NC, USA). Analysis of variances was performed for multiple comparison of each dependent variable. A P value 50.01 was considered to be statistically signi®cant.
DNase I footprinting analysis
DNase I footprinting analysis was performed to detect possible changes in the binding pattern of transcription factors due to the mutations found in the promoter region of the human MnSOD gene from the tumor cell lines. Brie¯y, the promoter region (7210 to +24) was subcloned into a pUC18 plasmid between KpnI and HindIII sites. A SacI/HindIII fragment was isolated from a 2% agarose gel in 0.56 Tris-borate buer using a dialysis tubing (Gibco ± BRL) and dephosphorylated by an alkaline phosphatase from calf intestinal (CIP, New England Biolabs). The puri®ed fragment was labeled with g 32 P at 5' hydroxyl terminus by T4 polynucleotide kinase (Promega) and digested with KpnI to generate a single end-labeled fragment. Puri®ed SP-1 and AP-2 proteins (Promega) were incubated with each labeled promoter fragment, and the DNA was partially digested by RNAse-Free DNase I. The samples were separated on a 6% polyacrylamide sequencing gel. The gel was vacuum dried and exposed to an X-ray ®lm (Eastman Kodak Co.) at 770 8C for 16 h.
